During the past decade, Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 13 clinical trials were completed, i.e. on average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" #1 sponsor was "Pfizer" with 7 trials, followed by "Bristol-Myers Squibb" with 5 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Celgene" with 1 trials sponsored and "Fresenius Kabi SwissBioSim GmbH" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" are "Arthritis, Psoriatic" (3 trials), "Psoriasis" (3 trials), "Rheumatoid Arthritis" (3 trials), "Spondylitis, Ankylosing" (2 trials) and "Systemic Lupus Erythematosus" (2 trials). Many other conditions were trialed in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" in a lesser frequency.

Most popular intervention types in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" are "Drug" (16 trials), "Other" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "BMS-986165" (3 trials), "Adalimumab" (2 trials), "Guselkumab" (2 trials) and "Adalimumab - GP2017" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".